IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

NCT03381183 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Metastatic Squamous Cell Carcinoma
Oral Cavity Squamous Cell Carcinoma
Oropharynx Squamous Cell Carcinoma
Paranasal Sinus Squamous Cell Carcinoma
Hypopharynx Squamous Cell Carcinoma
Larynx Squamous Cell Carcinoma

Interventions

DRUG: Durvalumab
DRUG: IRX-2 Regimen

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]